Skip to main content

The project of this Spanish and Japanese small molecule CDMO (Contract Development & Manufacturing Organization) will bring an investment of 100 million US dollars, increasing a 30% API production capacity and creating 100 new jobs by first half of 2024.

Barcelona, April 6, 2022 – AGC Pharma Chemicals, based in Spain and Japan, manufacturing small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, has decided to expand even more the site of Malgrat de Mar, Barcelona.

The expansion of the CDMO means a 7,500 square meters floor of building area and the implementation of new reactors with a volume from 1.5 to 7.5 m3, including the production capability to handle pharmaceutical compounds HPAPIs. In addition, the company has already planned another important investment soon, and for that the new building will have additional space for this future project.

In terms of Sustainability, as a member of the Responsible Care® Program, a global chemical industry’s voluntary initiative, AGC Pharma Chemicals will build up and operate the new plant minimizing its impacts to the community and the environment.

Also, the enterprise has recently invested in a larger R&D building, in the transformation to multi-purpose concept plant and in a micronizer unit. Thanks to all these projects, the CDMO company will be fully capable of producing a wide range of APIs and intermediates, offering the knowledge of handling flourine as one of their services.

The small molecule CDMO market is growing at over 7% annually, while the number of contracts handled by the companies are growing at an even faster rate. With this capacity expansion AGC Pharma Chemicals is prepared to satisfy this strong demand of the industry, focusing on their mission: to improve people´s lives by bringing their best quality products.

ABOUT US

AGC Pharma Chemicals is a Global Contract Development and Manufacturing Organization (CDMO), based in Spain and Japan, manufacturing small molecule Active Pharmaceutical Ingredients (APIs) and intermediates with solid business growth and financial stability as a part of AGC Group.

AGC Group is a global business conglomerate with over 200 companies, more than 55,800 employees and extending into over 30 countries with net sales of € 12,731 million (Y120 = €1) during 2020.

Under its medium-term management plan AGC plus-2023, the AGC Group has positioned its Life Science business, including its small molecule CDMO services, as one of its strategic businesses.

Latest News

Events & ConventionsAGC Pharma Chemicals at BOS Manchester 2024
12th November 2024

AGC Pharma Chemicals at BOS Manchester 2024

We are thrilled to announce our participation in BOS (Biotech Outsourcing Strategies) Manchester 2024, November 26-27.   BOS Manchester 2024's scope is primarily development stage CMC outsourcing for both Small Molecules…
Supply ChainAGC Pharma Chemicals Joins the Pharmaceutical Supply Chain Initiative as a Supplier Partner
6th November 2024

AGC Pharma Chemicals Joins the Pharmaceutical Supply Chain Initiative as a Supplier Partner

AGC Pharma Chemicals, a global contract development and manufacturing organization (CDMO) specializing in small-molecule APIs and intermediates, is proud to announce its new partnership with the Pharmaceutical Supply Chain Initiative…
Events & ConventionsAGC Pharma Chemicals at Bio Europe Stockholm 2024
1th November 2024

AGC Pharma Chemicals at Bio Europe Stockholm 2024

We are excited to be attending Bio Europe 2024 in Stockholm from November 4-6. Our team, represented by Business Development Associate Directors Monica Delgado and João Madeira do Ó, will…